As of 28 Mai 2020, more than 5 593 631 cases of confirmed COVID-19 have been documented globally with over 353 334 deaths The COVID-19 patients have common presentations like the influenza patients include fever, dry cough, and difficulty of breath Parallel evidence indicates that the risk of disease increases with critically chronic lung patients No strong efficacy to use drugs on the market We apply drug design computer techniques to find the expected drug for COVID-19 after knowing the repurposing the detailed of 3D-structures of its key proteins The combination of the analyzed spectra of the antimalarial/antiviral drugs: Chloroquine (CQ)/Umifenovir, Hydroxychloroquine (HQ)/Umifenovir and Amodiaquine (ADQ)/Umifenovir have been discussed to give an additional information about the investigated set of complex drugs The aim of this work is the bioinformatic study of COVID_19 inhibition by antimalarial/antiviral combined drugs
Computational predictions and comparative structural analysis for 4-aminoquinoline/Umifenovir drug combinations towards drug for coronavirus disease-19 (COVID-19)